

3. (Amended) The therapeutic agent according to claim 1 or 2, wherein the therapeutic agent for hypercalcemia is chosen from at least one of a bone resorption-inhibiting agent, a calcium excretion-promoting agent, an agent for inhibiting intestinal absorption of calcium, and a loop diuretic.

5. (Amended) The therapeutic agent according to claim 4, wherein the bone resorption-inhibiting agent is at least one of bisphosphonate or calcitonin.

6. (Amended) The therapeutic agent according to any one of claims 1 or 2, wherein the active ingredient is an antagonist for the PTHrP receptor.

7. (Amended) The therapeutic agent according to any one of claims 1 or 2, wherein the active ingredient is an anti-PTHrP antibody.

8. (Amended) The therapeutic agent according to any one of claims 1 or 2, wherein the active ingredient is a fragment of an anti-PTHrP antibody and/or a modified form of the fragment.

10. (Amended) The therapeutic agent according to claim 7, wherein the antibody is chosen from at least one of a human antibody, a humanized antibody, and a chimeric antibody.

13. (Amended) The therapeutic agent according to any one of claims 1 or 2, wherein the drug-resistant hypercalcemia is caused by cancer.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

Please add new claims 14-16 as follows:

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

13. (New) The therapeutic agent according to claim 5, wherein the active ingredient is chosen from at least one of